Abstract
Summary
To advance our understanding of the burden of fractures among men, we studied a group of men at high risk for low bone strength due to lung disease. We found high rates of fractures but low rates of bone density testing that could predict fracture before it occurs.
Introduction
To advance understanding of the burden of fragility fractures and attention to bone health among men with chronic obstructive lung disease (COPD), we quantified rates of fragility fracture, bone density testing, and anti-resorptive treatment and calculated the number needed to screen (NNS) to prevent one hip fracture in a cohort of men with COPD.
Methods
Veterans Administration (VA) and VA–Medicare administrative data permitted a retrospective cohort study of 87,360 men aged 50 and older, newly diagnosed with COPD between 1999 and 2003. Logistic regression models including patient characteristics, morbidities, and medication use assessed the effect of covariates on fracture and probability of testing or treatment.
Results
Mean age was 66.8. Hip and wrist fracture rates were 3.99 and 1.31 per 1,000 person years, respectively. Mean follow-up was 2.67 years; 4.4% underwent bone densitometry; 2.8% filled anti-resorptive prescriptions. Age, white race/ethnicity, more COPD exacerbations, barbiturate use, and anti-Parkinson’s drug use were significantly associated with fracture. Age, and systemic corticosteroids were most significantly associated with testing or treatment. Based on published adherence and treatment effects, the cohort’s calculated NNS to prevent one hip fracture is 432.
Conclusions
Fracture rate was high and testing and treatment uncommon. The NNS of 432 to prevent one hip fracture is smaller than 731, the NNS for women aged 65–69 for whom universal screening is recommended. Attention to the bone health of this population is warranted. Future research must determine how testing and treatment impact overall quality of life and mortality of men with COPD.
Similar content being viewed by others
References
Bass E, French DD, Bradham DD, Rubenstein LZ (2007) Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 17(7):514–519
Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51(3):364–370
Haentjens P, Lamraski G, Boonen S (2005) Costs and consequences of hip fracture occurrence in old age: an economic perspective. Disabil Rehabil 27(18–19):1129–1141
Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897–902
Khasraghi FA, Lee EJ, Christmas C, Wenz JF (2003) The economic impact of medical complications in geriatric patients with hip fracture. Orthopedics 26(1):49–53, discussion 53
Biskobing DM (2002) COPD and osteoporosis. Chest 121(2):609–620
Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS (1999) Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 116(6):1616–1624
Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E (2009) Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int 21:1341–1349
Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132(5):1599–1607
Sin DD, Man JP, Man SF (2003) The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114(1):10–14
Lekamwasam S, Trivedi DP, Khaw KT (2005) An association between respiratory function and hip bone mineral density in older men: a cross-sectional study. Osteoporos Int 16(2):204–207
Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V (2007) The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 101(1):177–185
Shane E, Silverberg SJ, Donovan D et al (1996) Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 101(3):262–269
Papaioannou A, Parkinson W, Ferko N et al (2003) Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int 14(11):913–917
Li L, Brennan KJ, Gaughan JP, Ciccolella DE, Kuzma AM, Criner GJ (2008) African Americans and men with severe COPD have a high prevalence of osteoporosis. COPD 5(5):291–297
Barr RG, Celli BR, Mannino DM et al (2009) Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 122(4):348–355
Franco CB, Paz-Filho G, Gomes PE et al (2009) Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int 20:1881–1887
Carter JD, Patel S, Sultan FL et al (2008) The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. Respir Med 102(8):1165–1172
Penrod JD, Litke A, Hawkes WG et al (2008) The association of race, gender, and comorbidity with mortality and function after hip fracture. J Gerontol A Biol Sci Med Sci 63(8):867–872
Vestergaard P, Rejnmark L, Mosekilde L (2007) Increased mortality in patients with a hip fracture-effect of pre-morbid conditions and post-fracture complications. Osteoporos Int 18(12):1583–1593
de Luise C, Brimacombe M, Pedersen L, Sorensen HT (2008) Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study. Eur J Epidemiol 23(2):115–122
Leech JA, Dulberg C, Kellie S, Pattee L, Gay J (1990) Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 141(1):68–71
McKnight J, Scott A, Menzies D, Bourbeau J, Blais L, Lemiere C (2005) A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. J Clin Epidemiol 58(2):206–208
Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Med Care 47(1):69–72
Curtis JR, Taylor AJ, Matthews RS et al (2009) “Pathologic” fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int 20:1969–1972
Karter AJ, Parker MM, Moffet HH, Ahmed AT, Schmittdiel JA, Selby JV (2009) New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 44(5 Pt 1):1640–1661
Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L (2005) Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6:39
Nelson HD, Helfand M, Woolf SH, Allan JD (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137(6):529–541
Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME (2008) Adherence to alendronate in male veterans. Osteoporos Int 19(3):349–356
Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9(1):29–37
Ettinger B, Black D, Dawson-Hughes B, Pressman A, Melton JL (2010) Updated fracture incidence rates for US version of FRAX. Osteoporos Int 21:25–33
Jorgensen NR, Schwarz P (2008) Osteoporosis in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 14(2):122–127
Daniell HW (1972) Osteoporosis and smoking. JAMA 221(5):509
Lewiecki EM, Gordon CM, Baim S et al (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43(6):1115–1121
Lim LS, Hoeksema LJ, Sherin K (2009) Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 36(4):366–375
National Osteoporosis Foundation (2008) The clinician’s guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/clinicians_guide.htm. Accessed June 17, 2009
Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Forciea MA, Owens DK (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148(9):680–684
Affairs VDCPGUSDoV (2007) Management of Chronic Obstructive Pulmonary Disease (COPD). http://www.healthquality.va.gov/Chronic_Obstructive_Pulmonary_Disease_COPD.asp. Accessed August 27, 2010
Piette JD, Heisler M (2004) Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manage Care 10(11 Pt 2):861–868
Department of Veterans Affairs (2010) Federal benefits for veterans, dependents & survivors. http://www1.va.gov/opa/publications/benefits_book/federal_benefits.pdf. Accessed August 26
Acknowledgments
Nancy E. Morden received funding from VA ORH Rural Health Resource Center—Eastern Region and Todd A. Lee from A HSR&D IIR 03-307.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Appendix A
Appendix A
Rights and permissions
About this article
Cite this article
Morden, N.E., Sullivan, S.D., Bartle, B. et al. Skeletal health in men with chronic lung disease: rates of testing, treatment, and fractures. Osteoporos Int 22, 1855–1862 (2011). https://doi.org/10.1007/s00198-010-1423-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-010-1423-y